5 results on '"Maria LUCENTE"'
Search Results
2. Therapeutic Efficacy of Autologous Non-Mobilized Enriched Circulating Endothelial Progenitors in Patients With Critical Limb Ischemia ― The SCELTA Trial ―
- Author
-
Stefano Michelagnoli, Benedetta Mazzanti, Francesco Liotta, Eleonora Amelia Maria Lucente, Giulia Carli, Enrico Maggi, Nicola Troisi, Sergio Castellani, Francesco Annunziato, Lorenzo Cosmi, Clara Pigozzi, Valentina Querci, Filippo Bartalesi, Gabriele Graziani, Manlio Acquafresca, Grazia Panigada, Paolo Fontanari, Beatrice Dilaghi, Brunetto Alterini, Paola Romagnani, Cristiana Baggiore, Giovanni Castellini, Carlo Pratesi, Walter Dorigo, Veronica Santarlasci, Paola Parronchi, Edoardo Mannucci, Alessandro Bartoloni, Filippo Fassio, Giancarlo Landini, Aaron Fargion, Gian Franco Gensini, Benedetta Bartolozzi, Guido Bellandi, Maria Boddi, Riccardo Saccardi, Carolina Orsi Battaglini, and Sergio Romagnani
- Subjects
Male ,0301 basic medicine ,medicine.medical_specialty ,Angiogenesis ,medicine.medical_treatment ,Urology ,CD34 ,Bone Marrow Cells ,030204 cardiovascular system & hematology ,Transplantation, Autologous ,Amputation, Surgical ,03 medical and health sciences ,0302 clinical medicine ,Ischemia ,Clinical endpoint ,Humans ,Medicine ,Aged ,Bone Marrow Transplantation ,Endothelial Progenitor Cells ,business.industry ,Therapeutic effect ,Extremities ,General Medicine ,Critical limb ischemia ,Middle Aged ,Survival Analysis ,Autotransplantation ,030104 developmental biology ,medicine.anatomical_structure ,Leukocytes, Mononuclear ,Female ,Bone marrow ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Perfusion - Abstract
Background The therapeutic efficacy of bone marrow mononuclear cells (BM-MNC) autotransplantation in critical limb ischemia (CLI) has been reported. Variable proportions of circulating monocytes express low levels of CD34 (CD14+CD34lowcells) and behave in vitro as endothelial progenitor cells (EPCs). The aim of the present randomized clinical trial was to compare the safety and therapeutic effects of enriched circulating EPCs (ECEPCs) with BM-MNC administration.Methods and Results:ECEPCs (obtained from non-mobilized peripheral blood by immunomagnetic selection of CD14+and CD34+cells) or BM-MNC were injected into the gastrocnemius of the affected limb in 23 and 17 patients, respectively. After a mean of 25.2±18.6-month follow-up, both groups showed significant and progressive improvement in muscle perfusion (primary endpoint), rest pain, consumption of analgesics, pain-free walking distance, wound healing, quality of life, ankle-brachial index, toe-brachial index, and transcutaneous PO2. In ECEPC-treated patients, there was a positive correlation between injected CD14+CD34lowcell counts and the increase in muscle perfusion. The safety profile was comparable between the ECEPC and BM-MNC treatment arms. In both groups, the number of deaths and major amputations was lower compared with eligible untreated patients and historical reference patients. Conclusions This study supports previous trials showing the efficacy of BM-MNC autotransplantation in CLI patients and demonstrates comparable therapeutic efficacy between BM-MNC and EPEPCs.
- Published
- 2018
3. Variation in Immune-Related microRNAs Profile in Human Milk Amongst Lactating Women
- Author
-
Maria Lucente, Maria Cristina Caroleo, Guido Moro, Roberto Cannataro, Luca Gallelli, Erika Cione, Ida Francesca De Luca, Mariarita Perri, and Giovambattista De Sarro
- Subjects
animal diseases ,Cell ,Biology ,HUMAN COLOSTRUM ,Biological fluid ,Immune system ,Pregnancy ,microRNA ,medicine ,Humans ,Lactation ,Orthopedics and Sports Medicine ,Immune homeostasis ,Milk, Human ,Colostrum ,Genetic Variation ,General Medicine ,MicroRNAs ,medicine.anatomical_structure ,Gene Expression Regulation ,Immunology ,Emergency Medicine ,Acquired immune response ,Pasteurization ,Female ,Biomarkers - Abstract
Background Human Milk (HM) is a biological fluid representing the first nutrient for newborns. It directly impacts the development of the infant's immune system. In this concern, specific microRNAs (miRNAs) such as hsa-miR-21, hsa-miR-181a, hsa-miR-150 and hsa-miR-223 are known to be involved in the innate and acquired immune response. Objective Herein, these miRNAs were evaluated in frozen and pasteurized samples of human colostrum and HM in order to elucidate the distribution and the expression profile of these biological mediators in both biological fluids. Methods Using quantitative approach qRT-PCR, we analyzed immune-related microRNAs in both, colostrum and HM. Results Our study provided evidence of a comparable profile of immune specific miRNAs in colostrum and HM. Although we detected all the four miRNAs tested, we point out the prevalence of hsamiR- 181a and hsa-miR-223 indicative to act on T and granulocytes cell populations as selective targets. Therefore, these biomolecules could affect newborn's immune homeostasis at early stages of life. While, variation in immune-related miRNAs was found in HM amongst lactating women, it was not evidenced in colostrum. Of interest, pasteurization procedure did not alter the distribution or the expression profile of the miRNAs tested in both colostrum and HM. Herein, we also proposed a simple method to determine the quantity of these biomolecules in biological fluids. Conclusion Considering, this evidence the variation in immune-related miRNAs should be take into account and could be relevant for preterm and hospitalized infants who usually received pasteurized HM from donors.
- Published
- 2017
4. Innate Immunity and Human Milk MicroRNAs Content: A New Perspective for Premature Newborns
- Author
-
Maria Cristina Caroleo, Luca Gallelli, Giovambattista De Sarro, Erika Cione, Maria Lucente, and Filippo Luciani
- Subjects
0301 basic medicine ,medicine.medical_specialty ,Neonatal intensive care unit ,Innate immune system ,Neonatal sepsis ,business.industry ,lcsh:RJ1-570 ,lcsh:Pediatrics ,Context (language use) ,medicine.disease ,Sepsis ,03 medical and health sciences ,Low birth weight ,030104 developmental biology ,0302 clinical medicine ,Immune system ,Pediatrics, Perinatology and Child Health ,microRNA ,Medicine ,medicine.symptom ,business ,Intensive care medicine ,030215 immunology - Abstract
Context The premature newborns are prone to develop both early onset and late onset neonatal sepsis. The major causes of this phenomenon rely on the immaturity of the immune system, which has reduced capability to respond adequately to pathogens. Evidence Acquisition Titles and abstracts of previous papers were scanned before reading the full-text, in order to retrieve appropriate information. The databases used for searching were PubMed, Cochrane, and Embase for articles published before 1st of July, 2016. Secondary search for articles cited in reference lists were identified by the primary search. This review focused on neonatal sepsis incidence and the associated immune response with regards to microRNAs of human milk as a new microelement that enables regulation of innate immunity functions. Results Since human milk is a valuable source of microRNAs, a better understanding of its content will open a new therapeutic avenue for the clinical management of infectious diseases affecting premature newborns. The variation in miRNAs quantity in human milk needs to be considered. Mother’s milk can have different amounts of miRNAs and the identification of a microMilk batch richer of miRNAs can be a nutrition intervention method for modulating innate immunity in clinical management of premature newborns. Conclusions Routine translation of the microMilk concept for neonatal intensive care unit (NICU), in the management of premature newborns could be a way of defending premature newborns and Very Low Birth Weight (VLBW) infants from both early and late sepsis.
- Published
- 2017
5. Efficacy of a new technique - INtubate-RECruit-SURfactant-Extubate - 'IN-REC-SUR-E' - in preterm neonates with respiratory distress syndrome: study protocol for a randomized controlled trial
- Author
-
Francesco Torcetta, Maria Lucente, Alessandro Gambacorta, Anton H. van Kaam, Agostina Solinas, Francesca Tormena, Alessandra Grison, J. Jane Pillow, Diego Gazzolo, Fabio Mosca, Giancarlo Gargano, Lorenzo Quartulli, Francesca Paola Fusco, P.G. Matassa, Flavia Petrillo, Carlo Dani, Maria Paola Re, Alessandra Casati, Alessandra Lio, Valentina Vendettuoli, Milena Tana, Carolina Grassia, Maria Luisa Ventura, E. Ciarmoli, Paolo E Villani, Alex Staffler, Gaetano Ausanio, Marcello Vitaliti, Betta Pasqua, Ilaria Stasi, Caterina Cacace, Stefano Nobile, Federica Pontiggia, Lucio Giordano, Chiara Consigli, Antonello Del Vecchio, Claudia Aurilia, Viviana Cardilli, Gabriella Nigro, Chiara Tirone, Eleonora Balestri, Giovanna Mescoli, Luigi Orfeo, Isotta Guidotti, Stefania Vedovato, Antonio Scorrano, Laura Ilardi, Graeme R. Polglase, Alberto Berardi, Giuseppe Presta, Eloisa Gitto, Francesco Giura, Giovanni Vento, Camilla Gizzi, Lidia Grappone, Hubert Messner, Fabrizio Sandri, Enza Roma, Roberta Pastorino, Valerio Meli, Chiara Poggi, Loretta Mattia, Virgilio P. Carnielli, Stefano Martinelli, Gianfranco Maffei, Federica Ferrero, Roberto Perniola, Eugenia Maranella, Sara Dallaglio, Alberto Ricotti, Cinzia Ricci, Francesco Messina, Paolo Tagliabue, Isabella Mondello, Danila D’Onofrio, Filip Cools, Sandra Di Fabio, Roberto Bottino, Luca Boni, Luca Massenzi, Giovanna Montesano, Francesco Cota, Rosario Magaldi, Stefano Visentin, Mariarosa Colnaghi, Giampaolo Garani, Faculty of Medicine and Pharmacy, Clinical sciences, Growth and Development, and Neonatology
- Subjects
Male ,Time Factors ,medicine.medical_treatment ,HFOV ,INSURE ,Lung recruitment ,Preterm infants ,Airway Extubation ,Biological Products ,Caffeine ,Central Nervous System Stimulants ,Citrates ,Continuous Positive Airway Pressure ,Female ,High-Frequency Ventilation ,Humans ,Infant, Newborn ,Intubation, Intratracheal ,Phospholipids ,Pulmonary Surfactants ,Respiratory Distress Syndrome, Newborn ,Treatment Outcome ,Infant, Premature ,Medicine (miscellaneous) ,Pharmacology (medical) ,Study Protocol ,0302 clinical medicine ,Functional residual capacity ,030212 general & internal medicine ,Continuous positive airway pressure ,Respiratory Distress Syndrome ,Respiratory distress ,High-frequency ventilation ,medicine.anatomical_structure ,Settore MED/38 - PEDIATRIA GENERALE E SPECIALISTICA ,Anesthesia ,Breathing ,medicine.medical_specialty ,03 medical and health sciences ,030225 pediatrics ,medicine ,Intensive care medicine ,Premature ,Mechanical ventilation ,Lung ,business.industry ,Infant ,Newborn ,INSURE, Lung recruitment, Preterm infants, Medicine (miscellaneous), Pharmacology (medical) ,Intratracheal ,business ,Intubation - Abstract
Although beneficial in clinical practice, the INtubate-SURfactant-Extubate (IN-SUR-E) method is not successful in all preterm neonates with respiratory distress syndrome, with a reported failure rate ranging from 19 to 69 %. One of the possible mechanisms responsible for the unsuccessful IN-SUR-E method, requiring subsequent re-intubation and mechanical ventilation, is the inability of the preterm lung to achieve and maintain an “optimal” functional residual capacity. The importance of lung recruitment before surfactant administration has been demonstrated in animal studies showing that recruitment leads to a more homogeneous surfactant distribution within the lungs. Therefore, the aim of this study is to compare the application of a recruitment maneuver using the high-frequency oscillatory ventilation (HFOV) modality just before the surfactant administration followed by rapid extubation (INtubate-RECruit-SURfactant-Extubate: IN-REC-SUR-E) with IN-SUR-E alone in spontaneously breathing preterm infants requiring nasal continuous positive airway pressure (nCPAP) as initial respiratory support and reaching pre-defined CPAP failure criteria. In this study, 206 spontaneously breathing infants born at 24+0–27+6 weeks’ gestation and failing nCPAP during the first 24 h of life, will be randomized to receive an HFOV recruitment maneuver (IN-REC-SUR-E) or no recruitment maneuver (IN-SUR-E) just prior to surfactant administration followed by prompt extubation. The primary outcome is the need for mechanical ventilation within the first 3 days of life. Infants in both groups will be considered to have reached the primary outcome when they are not extubated within 30 min after surfactant administration or when they meet the nCPAP failure criteria after extubation. From all available data no definitive evidence exists about a positive effect of recruitment before surfactant instillation, but a rationale exists for testing the following hypothesis: a lung recruitment maneuver performed with a step-by-step Continuous Distending Pressure increase during High-Frequency Oscillatory Ventilation (and not with a sustained inflation) could have a positive effects in terms of improved surfactant distribution and consequent its major efficacy in preterm newborns with respiratory distress syndrome. This represents our challenge. ClinicalTrials.gov identifier: NCT02482766 . Registered on 1 June 2015.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.